肺疾患治療市場 - 世界の産業規模、シェア、動向、機会、予測：疾患タイプ別、治療タイプ別、薬剤クラス別、地域別、競合、2019年-2029年

肺疾患治療の世界市場規模は2023年に784億2,000万米ドルとなり、2029年までの予測期間のCAGRは5.89%で堅調な成長が予測されています。

肺疾患治療市場には、慢性閉塞性肺疾患（COPD）、喘息、肺線維症、肺がん、嚢胞性線維症など、肺に影響を及ぼす様々な呼吸器疾患への対処を目的とした医薬品や治療が幅広く含まれています。世界の罹患率および死亡率の主要原因の1つである肺疾患は、ヘルスケアの重要な課題であり、革新的な治療法を発見するための広範な研究開発が求められています。同市場は、気管支拡張薬、副腎皮質ステロイド薬、モノクローナル抗体、抗生物質、標的治療薬など、多様な治療選択肢によって特徴付けられています。

β-アゴニストや抗コリン薬などの気管支拡張薬は、気道の筋肉を弛緩させ、気流を改善し、息切れを軽減することで症状を緩和する役割を果たし、COPDや喘息などの疾患の管理の要となっています。副腎皮質ステロイドは経口または吸入で投与され、喘息やCOPD増悪などの症状における気道炎症を制御するのに重要な強力な抗炎症作用を有します。モノクローナル抗体は、特に重症の喘息やCOPDにおいて、疾患発症に関与する特定の炎症経路を標的とする有望な治療手段として浮上してきました。呼吸器感染症の治療には抗生物質が重要な役割を果たすが、この抗生物質は基礎疾患である肺の状態を悪化させ、疾患の進行に寄与することがあります。さらに、標的治療の登場は肺がんの治療状況に革命をもたらし、腫瘍の増殖を促すがん原性変異や分子経路を標的とする薬剤によって、より個別化された効果的な治療選択肢が提供されています。

市場はドラッグデリバリー技術の著しい進歩を目の当たりにしており、吸入デバイスやネブライザーの開発により、薬剤の有効性、患者のコンプライアンス、利便性が向上しています。さらに、大気汚染、喫煙、高齢化、環境暴露などの要因による肺疾患の有病率の上昇は、効果的な治療薬に対する需要の高まりを裏付けています。しかし、市場は厳しい規制要件、特許切れ、ジェネリック医薬品との競合、医薬品開発と商業化に伴う高コストなどの課題にも直面しています。このような課題にもかかわらず、疾病メカニズム、バイオマーカー、革新的な治療法に関する継続的な調査により、呼吸器疾患市場の継続的な成長と進化が期待されています。

主な市場促進要因

呼吸器疾患の有病率の増加

医薬品開発と研究の進歩

ドラッグデリバリーの技術革新

主な市場課題

規制上のハードル

特許切れとジェネリック競合

高い開発コスト

主な市場動向

精密医療の進歩

生物製剤と免疫療法の採用増加

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 VOC (顧客の声)

第5章 世界の肺疾患治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 疾患タイプ別（喘息、肺がん、慢性閉塞性肺疾患）
  • 治療タイプ別（化学療法、免疫療法、標的療法、放射線療法）
  • 薬剤クラス別（コルチコステロイド、気管支拡張薬、抗菌薬、アルキル化剤、Mucolytics）
  • 地域別
  • 企業別（2023）
• 市場マップ
  • 疾患タイプ別
  • 治療タイプ別
  • 薬剤クラス別
  • 地域別

第6章 アジア太平洋地域の肺疾患治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 疾患タイプ別
  • 治療タイプ別
  • 薬剤クラス別
  • 国別
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第7章 欧州の肺疾患治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 疾患タイプ別
  • 治療タイプ別
  • 薬剤クラス別
  • 国別
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第8章 北米の肺疾患治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 疾患タイプ別
  • 治療タイプ別
  • 薬剤クラス別
  • 国別
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第9章 南米の肺疾患治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 疾患タイプ別
  • 治療タイプ別
  • 薬剤クラス別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの肺疾患治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 疾患タイプ別
  • 治療タイプ別
  • 薬剤クラス別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • エジプト

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品の発売（ある場合）
• 合併および買収（ある場合）

第13章 世界の肺疾患治療市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• Novartis AG
• Johnson & Johnson Services, Inc.
• Amgen Inc.
• AstraZeneca Plc.
• Boehringer Ingelheim International GmbH
• Pfizer Inc.
• Allergan Inc.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F Hoffmann-La Roche Ltd.

第16章 戦略的提言

第17章 調査会社について・免責事項

Global Lung Disease Therapeutics Market was valued at USD 78.42 Billion in 2023 and is anticipated to project robust growth in the forecast period with a CAGR of 5.89% through 2029.

The lung disease therapeutics market encompasses a broad spectrum of pharmaceuticals and treatments aimed at addressing various respiratory conditions affecting the lungs, including chronic obstructive pulmonary disease (COPD), asthma, pulmonary fibrosis, lung cancer, and cystic fibrosis, among others. As one of the leading causes of morbidity and mortality worldwide, lung diseases present a significant healthcare challenge, prompting extensive research and development efforts to discover innovative therapies. The market is characterized by a diverse range of treatment options, including bronchodilators, corticosteroids, monoclonal antibodies, antibiotics, and targeted therapies.

Bronchodilators, such as beta-agonists and anticholinergics, serve to alleviate symptoms by relaxing the airway muscles, improving airflow, and reducing shortness of breath, thus representing a cornerstone in the management of conditions like COPD and asthma. Corticosteroids, administered orally or via inhalation, possess potent anti-inflammatory properties critical for controlling airway inflammation in conditions like asthma and COPD exacerbations. Monoclonal antibodies have emerged as a promising therapeutic avenue, particularly in severe asthma and COPD, targeting specific inflammatory pathways implicated in disease pathogenesis. Antibiotics play a crucial role in treating respiratory infections, which can exacerbate underlying lung conditions and contribute to disease progression. Moreover, the advent of targeted therapies has revolutionized the treatment landscape for lung cancer, with drugs targeting oncogenic mutations and molecular pathways driving tumor growth, thereby offering more personalized and effective treatment options.

The market is witnessing significant advancements in drug delivery technologies, with the development of inhalation devices and nebulizers improving drug efficacy, patient compliance, and convenience. Furthermore, the rising prevalence of lung diseases, driven by factors such as air pollution, smoking, aging populations, and environmental exposures, underscores the growing demand for effective therapeutics. However, the market also faces challenges, including stringent regulatory requirements, patent expirations, generic competition, and the high cost associated with drug development and commercialization. Despite these challenges, ongoing research into disease mechanisms, biomarkers, and innovative therapeutic modalities holds promise for the continued growth and evolution of the lung disease therapeutics market, with the goal of improving patient outcomes, quality of life, and reducing the global burden of respiratory diseases.

Key Market Drivers

Increasing Prevalence of Respiratory Diseases

The increasing prevalence of respiratory diseases is a significant driver fueling the growth of the global lung disease therapeutics market. Various factors contribute to the rising burden of respiratory conditions worldwide, including environmental pollution, tobacco smoking, aging populations, and changing lifestyles. As a result, respiratory diseases such as chronic obstructive pulmonary disease (COPD), asthma, lung cancer, and pulmonary fibrosis have become leading causes of morbidity and mortality, prompting a surge in demand for effective therapeutics.

COPD, characterized by chronic bronchitis and emphysema, affects millions of individuals globally and is a major contributor to the growing prevalence of respiratory diseases. Factors such as air pollution, occupational exposures to dust and chemicals, and smoking play a significant role in the development and progression of COPD. Similarly, asthma, a chronic inflammatory condition of the airways, affects over 300 million people worldwide and is influenced by genetic predisposition, environmental triggers, and allergen exposure. The increasing prevalence of asthma, particularly in urban areas with high levels of air pollution, underscores the need for improved therapeutics to manage symptoms and prevent exacerbations.

Lung cancer, a leading cause of cancer-related deaths worldwide, is closely linked to tobacco smoking, environmental carcinogens, and genetic factors. The rising incidence of lung cancer, coupled with advances in early detection and treatment, has led to a growing demand for targeted therapies and immunotherapies to improve patient outcomes. Pulmonary fibrosis, a progressive scarring of lung tissue, affects a significant number of individuals, with causes ranging from environmental exposures to genetic factors and autoimmune diseases. The increasing prevalence of pulmonary fibrosis highlights the need for innovative treatments to slow disease progression and improve quality of life.

The growing burden of respiratory diseases has led to increased healthcare spending on diagnosis, treatment, and management, driving market growth in the lung disease therapeutics sector. Pharmaceutical companies are investing in research and development to develop novel drugs, biologics, and targeted therapies to address unmet medical needs in respiratory medicine. Moreover, technological advancements in drug delivery systems, such as inhalers and nebulizers, enhance the efficacy and convenience of respiratory medications, further supporting market expansion.

Advancements in Drug Development and Research

Advancements in drug development and research play a pivotal role in boosting the global lung disease therapeutics market. Over the years, significant progress has been made in understanding the underlying mechanisms of respiratory diseases, leading to the identification of novel therapeutic targets and the development of innovative treatment modalities. One of the key drivers of advancements in drug development is the elucidation of specific molecular pathways involved in respiratory diseases such as chronic obstructive pulmonary disease (COPD), asthma, lung cancer, and pulmonary fibrosis. Through extensive research, scientists have identified various cytokines, inflammatory mediators, and signaling pathways that contribute to the pathogenesis of these conditions. This deeper understanding has paved the way for the development of targeted therapies aimed at modulating these pathways to mitigate disease progression and improve patient outcomes.

Moreover, advancements in genomics and personalized medicine have revolutionized the treatment landscape for lung diseases. Genetic studies have uncovered key genetic variants associated with susceptibility to respiratory conditions and differential responses to treatment. This knowledge enables healthcare providers to tailor treatment regimens based on individual patient characteristics, maximizing therapeutic efficacy, and minimizing adverse effects. Precision medicine approaches are increasingly being applied in the development of lung disease therapeutics, leading to more personalized and effective treatments.

In addition to targeted therapies, advancements in drug delivery technologies have contributed to the growth of the lung disease therapeutics market. Inhalation devices, including metered-dose inhalers (MDIs), dry powder inhalers (DPIs), and nebulizers, offer efficient and targeted delivery of medications directly to the lungs. These devices improve drug deposition in the respiratory tract, enhance patient compliance, and reduce systemic side effects compared to traditional oral medications. Furthermore, the development of long-acting and ultra-long-acting formulations extends the duration of drug action, reducing the frequency of dosing and improving patient convenience.

Technological Innovations in Drug Delivery

Technological innovations in drug delivery have significantly contributed to the growth and advancement of the global lung disease therapeutics market. These innovations have revolutionized the way respiratory medications are administered, improving efficacy, patient compliance, and overall treatment outcomes. One of the key advancements in drug delivery for lung diseases is the development of inhalation devices such as metered-dose inhalers (MDIs), dry powder inhalers (DPIs), and nebulizers. These devices allow for the targeted delivery of medications directly to the lungs, bypassing the gastrointestinal tract and delivering the drug where it is needed most. MDIs, which deliver a precise dose of medication with each actuation, are commonly used for the treatment of asthma and chronic obstructive pulmonary disease (COPD). DPIs, which deliver medications in the form of dry powder particles, offer an alternative for patients who may have difficulty coordinating their inhalation with the device. Nebulizers, which convert liquid medications into a fine mist for inhalation, are often used in the treatment of severe respiratory conditions or in patients who require higher doses of medication.

Advancements in formulation technologies have also played a significant role in improving drug delivery for lung diseases. Long-acting and ultra-long-acting formulations have been developed to extend the duration of drug action, reducing the frequency of dosing, and improving patient adherence to treatment regimens. For example, long-acting beta-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) are commonly formulated as inhalation powders or solutions for once-daily dosing, providing sustained bronchodilation in patients with COPD. Similarly, inhaled corticosteroids (ICS) combined with LABAs or LAMAs in fixed-dose combinations offer convenient and effective treatment options for patients with asthma or COPD.

Advancements in nanotechnology and biomaterials have led to the development of novel drug delivery systems for lung diseases. Nanoparticle-based drug carriers can improve the pharmacokinetics and tissue distribution of respiratory medications, enhancing their therapeutic efficacy and reducing systemic side effects. Inhalable liposomal formulations, for example, have been investigated for the targeted delivery of chemotherapy drugs in the treatment of lung cancer, minimizing off-target toxicity and improving patient tolerance to treatment.

Key Market Challenges

Regulatory Hurdles

One of the primary challenges facing the lung disease therapeutics market is navigating stringent regulatory requirements imposed by regulatory authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The process of obtaining regulatory approval for new drugs and therapies can be lengthy, complex, and expensive. Stringent clinical trial standards, safety assessments, and efficacy criteria must be met before a drug can be approved for market entry. Delays in the regulatory approval process can significantly impact the time-to-market for new therapies, delaying patient access to innovative treatments and hindering market growth.

Patent Expirations and Generic Competition

Patent expirations for blockbuster drugs in the lung disease therapeutics market pose a significant challenge to pharmaceutical companies, leading to increased competition from generic manufacturers. As patents expire, generic versions of branded medications enter the market, often at lower prices, leading to erosion of market share and revenue for originator companies. This loss of exclusivity can have a substantial impact on the profitability of branded drugs, prompting companies to explore strategies such as lifecycle management, product differentiation, and strategic partnerships to maintain market share and competitive advantage.

High Development Costs

The high cost of research and development (R&D) for lung disease therapeutics presents a formidable challenge for pharmaceutical companies. Developing new drugs from discovery to commercialization involves substantial investment in preclinical studies, clinical trials, regulatory submissions, and manufacturing processes. The cost of R&D is further exacerbated by the high failure rate of drug candidates in clinical trials, with many potential therapies failing to demonstrate safety or efficacy endpoints. Consequently, the high development costs associated with bringing new lung disease therapeutics to market pose a significant barrier, particularly for smaller biotechnology companies with limited financial resources.

Key Market Trends

Advancements in Precision Medicine

Advancements in precision medicine are catalyzing a transformative shift in the global lung disease therapeutics market, offering targeted and personalized treatment approaches that address the underlying molecular mechanisms of respiratory conditions such as chronic obstructive pulmonary disease (COPD), asthma, lung cancer, and pulmonary fibrosis. Precision medicine, also known as personalized or individualized medicine, utilizes genetic information, biomarkers, and other patient-specific factors to tailor therapies to individual characteristics. In the context of lung disease therapeutics, precision medicine has led to significant advancements in the identification of specific genetic mutations and molecular pathways implicated in disease pathogenesis.

One of the most notable advancements in precision medicine is the development of targeted therapies for lung cancer. Genetic studies have identified specific driver mutations, such as epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, and ROS1 rearrangements, which drive tumor growth in subsets of non-small cell lung cancer (NSCLC) patients. Targeted therapies such as tyrosine kinase inhibitors (TKIs) selectively inhibit these aberrant molecular pathways, leading to improved treatment outcomes and prolonged survival in patients with advanced NSCLC.

In addition to lung cancer, precision medicine approaches are also being applied to other respiratory conditions such as asthma and COPD. Genetic studies have identified genetic variants associated with increased susceptibility to asthma, as well as differential responses to asthma medications such as inhaled corticosteroids and beta-agonists. By identifying these genetic factors, clinicians can tailor treatment regimens to match the individual characteristics and needs of each patient, optimizing therapeutic efficacy and minimizing adverse effects.

Furthermore, precision medicine is driving the development of targeted biologics and immunotherapies for respiratory diseases. Monoclonal antibodies targeting specific inflammatory pathways, such as interleukin (IL)-4, IL-5, and IL-13, have shown efficacy in the treatment of severe asthma and eosinophilic COPD. Immunotherapies, including immune checkpoint inhibitors, have also shown promise in the treatment of lung cancer by harnessing the body's immune system to target cancer cells.

Rising Adoption of Biologics and Immunotherapies

The rising adoption of biologics and immunotherapies is reshaping the global lung disease therapeutics market, offering novel treatment options for respiratory conditions such as chronic obstructive pulmonary disease (COPD), asthma, lung cancer, and pulmonary fibrosis. Biologics, including monoclonal antibodies and recombinant proteins, target specific inflammatory pathways and molecular targets implicated in the pathogenesis of lung diseases, offering targeted and personalized treatment approaches for patients. In the treatment of severe asthma and COPD, biologics targeting key inflammatory mediators such as interleukin (IL)-4, IL-5, and IL-13 have shown promising results. These biologics, administered via subcutaneous or intravenous injection, help reduce airway inflammation, eosinophilic inflammation, and exacerbation rates in patients with severe asthma and COPD who are not adequately controlled with standard therapies. Notable examples include anti-IL-5 monoclonal antibodies such as mepolizumab, reslizumab, and benralizumab, which have demonstrated efficacy in reducing exacerbation rates and improving lung function in severe eosinophilic asthma.

In addition to asthma and COPD, biologics are also being investigated for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive fibrotic lung disease with limited treatment options. Biologics targeting key fibrotic pathways, including transforming growth factor-beta (TGF-B) and connective tissue growth factor (CTGF), have shown potential in preclinical and early clinical studies for the treatment of IPF. These biologics aim to inhibit the excessive deposition of extracellular matrix proteins and fibroblast proliferation, thereby slowing disease progression and preserving lung function in patients with IPF.

Immunotherapies, including immune checkpoint inhibitors, are revolutionizing the treatment of lung cancer by harnessing the body's immune system to target cancer cells. Immune checkpoint inhibitors such as programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors have demonstrated significant efficacy in the treatment of non-small cell lung cancer (NSCLC), particularly in patients with advanced or metastatic disease. These immunotherapies offer durable responses and improved survival outcomes compared to traditional chemotherapy regimens, leading to their widespread adoption as first-line and second-line treatments for NSCLC.

Segmental Insights

Disease Type Insights

Based on the disease type, asthma segment emerged as the dominant segment in the global lung disease therapeutics market in 2023. . Asthma, a widespread respiratory ailment affecting people of all ages, is a significant contributor to this dominance. Its escalating incidence, especially in urban settings characterized by elevated air pollution levels and allergen exposure, is fueling the need for efficient therapeutics to address the condition.

Asthma's prevalence globally underscores the importance of targeted treatments to manage its symptoms and prevent exacerbations. As such, pharmaceutical companies are increasingly focusing on developing innovative therapies tailored to address the specific needs of asthma patients. Additionally, advancements in medical research and technology are facilitating the discovery of novel therapeutic approaches, offering promising avenues for enhancing asthma management and improving patient outcomes. The dominance of the asthma segment in the lung disease therapeutics market reflects the substantial burden posed by this respiratory condition and the pressing demand for effective treatment options to alleviate its symptoms and enhance patients' quality of life.

Treatment Type Insights

Based on the treatment type, targeted therapy segment emerged as the dominant segment in the global lung disease therapeutics market in 2023. Targeted therapies represent a pivotal advancement in the treatment landscape by offering a personalized approach to addressing lung diseases. These therapies are designed to selectively target molecular pathways and genetic mutations involved in the pathogenesis of lung diseases, thereby enhancing treatment precision and efficacy.

In conditions like lung cancer, targeted therapies have demonstrated remarkable effectiveness in inhibiting tumor growth and improving patient outcomes. Specifically, they have shown promising results in individuals harboring specific genetic alterations such as epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, and ROS1 rearrangements. By directly targeting these aberrant molecular pathways, targeted therapies can effectively disrupt tumor progression and prolong survival in patients with these genetic mutations.

The dominance of the targeted therapy segment underscores the growing recognition of the importance of personalized medicine in lung disease treatment. As research continues to uncover novel molecular targets and genetic drivers of lung diseases, the role of targeted therapies is expected to further expand, offering new avenues for improving patient outcomes and quality of life.

Regional Insights

North America emerged as the dominant player in the global lung disease therapeutics market in 2023, holding the largest market share.This dominance can be attributed to the region's robust healthcare infrastructure and well-established pharmaceutical industry. North America boasts a plethora of leading pharmaceutical companies, esteemed research institutions, and renowned academic medical centers dedicated to advancing respiratory medicine. These entities collaborate synergistically to drive innovation, research, and development initiatives in the field of lung disease therapeutics.

The region's conducive regulatory environment, coupled with significant investments in healthcare and pharmaceutical research, further fortifies its position as a powerhouse in the global market. North America's proactive approach to healthcare innovation and its emphasis on cutting-edge therapies contribute to the continuous evolution and expansion of the lung disease therapeutics market. With a strong foundation in place, North America is poised to continue spearheading advancements in respiratory medicine, addressing unmet medical needs, and improving patient outcomes on a global scale.

Key Market Players

Novartis AG

Johnson & Johnson Services, Inc.

Amgen Inc.

AstraZeneca Plc

Boehringer Ingelheim International GmbH

Pfizer Inc.

Allergan Inc.

Bristol-Myers Squibb Company

Eli Lilly and Company

F Hoffmann-La Roche Ltd.

Report Scope:

In this report, the Global Lung Disease Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

********Lung Disease Therapeutics Market, By Disease Type:

Asthma Lung Cancer Chronic Obstructive Pulmonary Disease

*******Lung Disease Therapeutics Market, By Drug Class:

Corticosteroids Bronchodilator Antimicrobial Alkylating Agents Mucolytics

*********Lung Disease Therapeutics Market, By Treatment Type:

Chemotherapy Immunotherapy Targeted Therapy Radiation Therapy

Lung Disease Therapeutics Market, By Region:

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia-Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Lung Disease Therapeutics Market.

Available Customizations:

Global Lung Disease Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customers

5. Global Lung Disease Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Disease Type (Asthma, Lung Cancer, Chronic Obstructive Pulmonary Disease)
  • 5.2.2. By Treatment Type (Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy)
  • 5.2.3. By Drug Class (Corticosteroids, Bronchodilator, Antimicrobial, Alkylating Agents, Mucolytics)
  • 5.2.4. By Region
  • 5.2.5. By Company (2023)
• 5.3. Market Map
  • 5.3.1. By Disease Type
  • 5.3.2. By Treatment Type
  • 5.3.3. By Drug Class
  • 5.3.4. By Region

6. Asia Pacific Lung Disease Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease Type
  • 6.2.2. By Treatment Type
  • 6.2.3. By Drug Class
  • 6.2.4. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Lung Disease Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Disease Type
      • 6.3.1.2.2. By Treatment Type
      • 6.3.1.2.3. By Drug Class
  • 6.3.2. India Lung Disease Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Disease Type
      • 6.3.2.2.2. By Treatment Type
      • 6.3.2.2.3. By Drug Class
  • 6.3.3. Australia Lung Disease Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Disease Type
      • 6.3.3.2.2. By Treatment Type
      • 6.3.3.2.3. By Drug Class
  • 6.3.4. Japan Lung Disease Therapeutics Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Disease Type
      • 6.3.4.2.2. By Treatment Type
      • 6.3.4.2.3. By Drug Class
  • 6.3.5. South Korea Lung Disease Therapeutics Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Disease Type
      • 6.3.5.2.2. By Treatment Type
      • 6.3.5.2.3. By Drug Class

7. Europe Lung Disease Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease Type
  • 7.2.2. By Treatment Type
  • 7.2.3. By Drug Class
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Lung Disease Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Disease Type
      • 7.3.1.2.2. By Treatment Type
      • 7.3.1.2.3. By Drug Class
  • 7.3.2. Germany Lung Disease Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Disease Type
      • 7.3.2.2.2. By Treatment Type
      • 7.3.2.2.3. By Drug Class
  • 7.3.3. Spain Lung Disease Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Disease Type
      • 7.3.3.2.2. By Treatment Type
      • 7.3.3.2.3. By Drug Class
  • 7.3.4. Italy Lung Disease Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Disease Type
      • 7.3.4.2.2. By Treatment Type
      • 7.3.4.2.3. By Drug Class
  • 7.3.5. United Kingdom Lung Disease Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Disease Type
      • 7.3.5.2.2. By Treatment Type
      • 7.3.5.2.3. By Drug Class

8. North America Lung Disease Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease Type
  • 8.2.2. By Treatment Type
  • 8.2.3. By Drug Class
  • 8.2.4. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Lung Disease Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Disease Type
      • 8.3.1.2.2. By Treatment Type
      • 8.3.1.2.3. By Drug Class
  • 8.3.2. Mexico Lung Disease Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Disease Type
      • 8.3.2.2.2. By Treatment Type
      • 8.3.2.2.3. By Drug Class
  • 8.3.3. Canada Lung Disease Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Disease Type
      • 8.3.3.2.2. By Treatment Type
      • 8.3.3.2.3. By Drug Class

9. South America Lung Disease Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease Type
  • 9.2.2. By Treatment Type
  • 9.2.3. By Drug Class
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Lung Disease Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Disease Type
      • 9.3.1.2.2. By Treatment Type
      • 9.3.1.2.3. By Drug Class
  • 9.3.2. Argentina Lung Disease Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Disease Type
      • 9.3.2.2.2. By Treatment Type
      • 9.3.2.2.3. By Drug Class
  • 9.3.3. Colombia Lung Disease Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Disease Type
      • 9.3.3.2.2. By Treatment Type
      • 9.3.3.2.3. By Drug Class

10. Middle East and Africa Lung Disease Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Disease Type
  • 10.2.2. By Treatment Type
  • 10.2.3. By Drug Class
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Lung Disease Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Disease Type
      • 10.3.1.2.2. By Treatment Type
      • 10.3.1.2.3. By Drug Class
  • 10.3.2. Saudi Arabia Lung Disease Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Disease Type
      • 10.3.2.2.2. By Treatment Type
      • 10.3.2.2.3. By Drug Class
  • 10.3.3. UAE Lung Disease Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Disease Type
      • 10.3.3.2.2. By Treatment Type
      • 10.3.3.2.3. By Drug Class
  • 10.3.4. Egypt Lung Disease Therapeutics Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Disease Type
      • 10.3.4.2.2. By Treatment Type
      • 10.3.4.2.3. By Drug Class

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches (If Any)
• 12.3. Mergers & Acquisitions (If Any)

13. Global Lung Disease Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Novartis AG
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Johnson & Johnson Services, Inc.
• 15.3. Amgen Inc.
• 15.4. AstraZeneca Plc.
• 15.5. Boehringer Ingelheim International GmbH
• 15.6. Pfizer Inc.
• 15.7. Allergan Inc.
• 15.8. Bristol-Myers Squibb Company
• 15.9. Eli Lilly and Company
• 15.10. F Hoffmann-La Roche Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer